SLC5A2 and diabetic kidney disease: To date, therapeutic agents that modulate TNFR levels remain to be completely elucidated; however, several studies have revealed that treatment with sodium glucose cotransporter (SGLT2) inhibitor or Janus kinase (JAK) 1/2 inhibitor may decrease serum TNFR levels in patients with early and advanced DKD, respectively, whereas renin–angiotensin system inhibitor treatment did not alter TNFR levels in patients with early DKD (15).